Patient-centric clinical trials, those that are designed and executed with the patient perspective in mind, can accelerate enrollment and increase the probability of success. Patient-centered trials have not been widely adopted because it represents a fundamental change for what ultimately is a risk-averse and relatively slow moving industry. Parexel has employed its Patient Centric Protocol Optimization initiative in China.
Pharmaceutical Executive discussed opportunity for the implementation of patient-centric trials in China. As the entire life science industry booms there, clinical trials have been reformed as the government seeks to modernize the industry to position it as a global leader.
TrialSite News reported on Parexel and Eli Lilly’s research site and staff training initiative in China—a smart move to differentiate clinical trial brand in what will become the second most lucrative drug market.
Now the leading contract research organization (CRO) has implemented a potential model for patient-centric trials in China, as reported by Pharmaceutical Executive. Parexel actively educates the Chinese market about the benefits of patient-centric trials. That investment, although costly upfront, will produce dividends downstream.
Pharmaceutical Executive provides real-world case studies of Parexel’s Patient Centric Protocol Optimization (PCPO) methodology as it is employed in China.
What is PCPO?
We include a Parexel solution brief that includes important information. The CRO collateral introduces PCPO concepts and related activities during pre study, during study and during market access and beyond. In one example in China, the PCPO helped Parexel (and trial sponsor) take specific actions to improve patient enrollment and ultimately improved the overall clinical trial with a better chance at a positive outcome.